Snapshot

Why Mumbai–Thane–Navi Mumbai is iconic:
Mumbai and its adjoining industrial zones of Thane and Navi Mumbai form India’s oldest and most globally connected pharma ecosystem. The cluster is home to headquarters and flagship manufacturing plants of major global players such as Sun Pharma, Lupin, Cipla, Glenmark, Piramal, Wockhardt, and Aurobindo. It has a robust presence in formulations, APIs, oncology drugs, and R&D-driven specialty pharmaceuticals.

Industrial edge:

• Strong export focus, with numerous USFDA and EMA-approved facilities and DMF filings for 500+ APIs.
  
• Well-integrated infrastructure with R&D centers, pilot plants, SEZs, and clinical trial hubs.
  
• Preferred location for contract development & manufacturing (CDMO) and biopharma commercialization.
  

Scale: Over 2,000+ pharma companies, including top 10 Indian pharma exporters, contributing a major share of India’s $50B pharma export market.

Product Range

Category	Key Products
Formulations	Tablets, capsules, syrups, ointments, transdermal patches
Sterile Injectables	Vials, ampoules, lyophilized injectables, pre-filled syringes (PFS)
APIs (Bulk Drugs)	Antibiotics, anti-cancer APIs, antiretrovirals, KSMs
Oncology & Specialty Drugs	Cytotoxic injectables, targeted therapies, biologics
OTC & Nutraceuticals	Vitamins, supplements, ayurvedic and herbal medicines
Biopharma & Biosimilars	mAbs, insulin, vaccines, recombinant proteins
CDMO Services	End-to-end product development, scaling, packaging, and regulatory support

Cluster Strengths

Feature	Details
Legacy Pharma Capital	Hub of Indian pharma since pre-independence; HQ of major Indian MNCs
Global Market Access	Largest concentration of USFDA, EMA, MHRA-approved facilities in India
R&D & Clinical Trial Ecosystem	200+ R&D centers, bioequivalence (BE) study labs, and CROs
Port & Logistics Advantage	JNPT (Nhava Sheva) Port and Sahar International Airport provide unmatched logistics
CDMO & Innovation	Piramal Pharma, Glenmark, Lupin, Sun Pharma lead in CDMO & innovation pipelines
Skilled Talent & Institutions	Proximity to IIT Bombay, ICT Mumbai, NIPER, NMIMS, BITS campuses

Materials & Sustainability

Key Materials: APIs, solvents, excipients, vials, blister packs, injectable-grade syringes, controlled-substance ingredients, biotech media.

Sustainability Edge:

• Pharma SEZs with Zero Liquid Discharge (ZLD) infrastructure
  
• Extensive solvent recovery systems, minimizing environmental impact
  
• Solar energy adoption and EHS (Environment, Health, Safety) certification compliance
  
• Green supply chain practices promoted under Maharashtra Industrial Policy
  

Cluster Infrastructure

• Industrial Estates:
  
  • MIDC Thane, Rabale, Taloja (API & formulations)
    
  • SEEPZ SEZ, Navi Mumbai SEZ (biopharma & R&D hubs)
    
  • TTC Industrial Area (contract manufacturing units)
    
• Institutions:
  
  • ICT Mumbai (Asia’s top chemical engineering school)
    
  • NIPER Hajipur-Mumbai Extension
    
  • FDA Maharashtra HQ and CDSCO Western Zonal Office
    
• Connectivity:
  
  • JNPT (Nhava Sheva) Port for bulk and container exports
    
  • Mumbai International Airport’s pharma cargo hub (largest in India)
    
  • Western Dedicated Freight Corridor proximity
    

Compliance & Certifications

• USFDA, EMA, MHRA, ANVISA, TGA, WHO GMP certifications
  
• ISO 9001, ISO 14001, ISO 45001, ISO 17025 for QA/QC
  
• ICH Q7, Q8, Q9, Q10-compliant facilities
  
• Serialization compliance (EU FMD, US DSCSA)
  
• NABL-accredited testing labs for bioequivalence and stability studies
  

Production Timelines & MOQs

Product Type	Sampling Lead Time	Bulk Lead Time	MOQ Guidance
Generic Tablets & Capsules	2–3 weeks	5–7 weeks	500,000–1M tablets per SKU
Sterile Injectables (Vials/PFS)	3–4 weeks	8–10 weeks	100,000+ units
Oncology & High-Potency Products	4 weeks	8–12 weeks	Project-specific
APIs & Bulk Drugs	2–3 weeks	6–8 weeks	100–500 kg per API
Nutraceuticals & OTC	2 weeks	4–6 weeks	50,000+ bottles/cartons
CDMO/Custom Projects	3–4 weeks (dev)	8–12 weeks	Based on scope

Branding & Packaging

• Branding: GS1 serialization, tamper-evident labels, QR traceability, and holographic seals
  
• Packaging:
  
  • Alu-alu blister packs, HDPE containers, and vial crating
    
  • Serialization-ready secondary packaging (EU FMD/US DSCSA)
    
  • ISPM-15-compliant pallets for export
    
  • Cold-chain packaging for biologics and vaccines
    

Quality Control (IndiaUnbox Protocol)

• HPLC, GC-MS, LC-MS/MS-based API purity and stability testing
  
• BE/PK study capabilities in certified CROs
  
• Sterility and microbial testing for injectables
  
• In-process controls per ICH guidelines
  
• Export QC audits by SGS, TUV, Intertek for regulated shipments
  

Price Drivers

• API sourcing cost (domestic vs. imported KSMs)
  
• Facility compliance (USFDA, EU GMP) and DMF filing costs
  
• Investment in high-potency and sterile injectable facilities
  
• Packaging complexity (serialization, cold-chain logistics)
  
• Maharashtra’s Pharma Industrial Policy incentives reduce total landed costs
  

Buyer Confidence Signals

• Mumbai–Thane–Navi Mumbai cluster is India’s original pharma powerhouse, with 70+ years of global supply experience.
  
• Top 10 Indian exporters (Sun, Cipla, Lupin, Glenmark, Wockhardt, Piramal) operate here with global regulatory clearances.
  
• Strong CDMO ecosystem and early-to-market advantage for generics and specialty products.
  
• Seamless logistics via JNPT port and Mumbai Airport Pharma Cargo Hub (largest in India).
  
• Proven expertise in oncology, injectables, biosimilars, and controlled-substance drugs.